Ying Luo Sells 10,136 Shares of Gyre Therapeutics (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) CEO Ying Luo sold 10,136 shares of Gyre Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the sale, the chief executive officer owned 2,565,226 shares in the company, valued at $20,624,417.04. This represents a 0.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ying Luo also recently made the following trade(s):

• On Tuesday, May 5th, Ying Luo sold 179 shares of Gyre Therapeutics stock. The shares were sold at an average price of $8.01, for a total transaction of $1,433.79.

Gyre Therapeutics Trading Up 5.7%

GYRE opened at $7.47 on Friday. Gyre Therapeutics, Inc. has a twelve month low of $6.57 and a twelve month high of $11.78. The firm has a market cap of $724.52 million, a price-to-earnings ratio of -82.99 and a beta of 2.03. The company has a fifty day simple moving average of $7.58 and a 200 day simple moving average of $7.69.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings data on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The firm had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a positive return on equity of 3.14% and a negative net margin of 5.44%. On average, analysts forecast that Gyre Therapeutics, Inc. will post -0.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Gyre Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in Gyre Therapeutics by 28.6% in the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after acquiring an additional 89,390 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares during the period. Millennium Management LLC bought a new stake in shares of Gyre Therapeutics in the 3rd quarter worth approximately $267,000. State Street Corp lifted its holdings in shares of Gyre Therapeutics by 10.7% in the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after purchasing an additional 19,472 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in Gyre Therapeutics during the 3rd quarter valued at approximately $111,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Wall Street Zen lowered Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Zacks Research cut Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.